NUCLEAI
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.
NUCLEAI
Industry:
Artificial Intelligence Health Care Machine Learning
Founded:
2017-01-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.nucleaimd.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
46.5 M USD
Technology used in webpage:
SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Amazon IPv6 Google Apps For Business Cloudflare Hosting
Similar Organizations
mfine
Mfine is a health-tech startup developing an AI-powered telemedicine mobile app.
Navina
Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.
Neteera
Neteera developed an AI-powered sensing platform to reduce treatment failures & improve outcomes in health screening, diagnosis & treatment.
TuSimple
TuSimple is a self-driving truck company developing technology that allows them to drive from depot-to-depot without human intervention.
Visit
AI driven chatbot to provide health advice within minutes.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fosun RZ Capital
Fosun RZ Capital investment in Series B - Nucleai
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Series B - Nucleai
Grove Ventures
Grove Ventures investment in Series B - Nucleai
Vertex Ventures Israel
Vertex Ventures Israel investment in Series B - Nucleai
Section 32
Section 32 investment in Series B - Nucleai
Sanofi Ventures
Sanofi Ventures investment in Series B - Nucleai
Vertex Ventures Israel
Vertex Ventures Israel investment in Series A - Nucleai
Grove Ventures
Grove Ventures investment in Series A - Nucleai
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Series A - Nucleai
Grove Ventures
Grove Ventures investment in Seed Round - Nucleai
Official Site Inspections
http://www.nucleaimd.com
- Host name: cloudproxy10179.sucuri.net
- IP address: 192.124.249.179
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Nucleai"
Homepage 2024 - Nucleai
Nucleai’s technology stands out by being the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program. Our platform …See details»
Nucleai - Crunchbase Company Profile & Funding
Apr 3, 2018 · Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai received backing from …See details»
Nucleai Company Overview, Contact Details & Competitors | LeadIQ
Learn more about Nucleai's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ.See details»
Nucleai - LinkedIn
Nucleai Brings AI-powered spatial biology technology to the forefront of precision medicine to improve drug development, clinical treatment decisions, and patient outcomes. Nucleai works …See details»
Nucleai | Company | Mindmaps
Nucleai is a company that uses AI technology to improve drug development and patient outcomes in the field of spatial biology. They have a platform that utilizes tissue datasets to gain insights …See details»
Nucleai Secured $6.5M Series-A Initial Closing Led by Debiopharm …
Jul 7, 2020 · TEL AVIV and LAUSANNE, Switzerland, July 7, 2020 /PRNewswire/ -- Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision …See details»
Nucleai Secured $6.5m Series-A Initial Closing Led by
Jul 7, 2020 · Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. …See details»
Nucleai Secured $6.5M Series-A Initial Closing Led by ... - BioSpace
Jul 7, 2020 · Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision oncology platform for research and treatment decisions and Debiopharm …See details»
Privacy Policy - Nucleai
Nucleai Inc. (“we”, “our”, “us”) are committed to protecting and respecting your privacy. We are a company established in Israel with a registered office at 20 W Kinzie St, Chicago, IL 60654, …See details»
Nucleai and Merck KGaA - Business Wire
Jun 24, 2021 · As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified …See details»
Nucleai and Debiopharm Launch Research Collaboration
Jan 14, 2021 · Nucleai is a global provider of AI-powered pathology-based biomarker discovery that transforms the way pathology data is used throughout the research and development of …See details»
Nucleai and Merck KGaA Darmstadt, Germany Launch
Jun 24, 2021 · CHICAGO — Nucleai ( www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker …See details»
NUCLEAI AND DEBIOPHARM LAUNCH RESEARCH …
Nucleai is a global provider of AI-powered pathology-based biomarker discovery that transforms the way pathology data is used throughout the research and development of novel therapies. …See details»
Nucleai and Debiopharm Launch Research Collaboration Utilizing …
Jan 14, 2021 · Having become one of Debiopharm's investment portfolio companies in 2020 (Series A), Nucleai's pathology-based platform analyzes tissue images using computer vision …See details»
Nucleai : and Merck KGaA Darmstadt, Germany Launch …
Jun 24, 2021 · As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified …See details»
Profile Nucleai IIA-CHA-BIH Oncology - bihealth.org
AI-based tissue modeling engine intended to identify and segment various types in pathology slides including tumor, benign, and necrotic tissues. The engine also detects different types of …See details»
Nuclear organization - Wikipedia
Nuclear organization refers to the spatial organization and dynamics of chromatin within a cell nucleus during interphase. There are many different levels and scales of nuclear organisation. …See details»
Nucleai and Debiopharm Launch Research Collaboration Utilizing …
Jan 14, 2021 · TEL AVIV, Israel, and LAUSANNE, Switzerland, Jan. 14, 2021 /PRNewswire/ -- Nucleai (www.Nucleaimd.com), a global provider in pathology-based bioma...See details»